A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
This research study is for young people between 12 and 17 years old who have a long-lasting blood condition called chronic Immune Thrombocytopenia (ITP). ITP causes a low number of platelets, which are important for blood clotting. The study wants to find the best dose of a new medicine, efgartigimod, given through a drip, to help manage ITP. Participants will first receive either the study medicine or a dummy medicine (placebo) for up to 24 weeks without knowing which one they have. Afterwards, everyone will receive the study medicine for at least one year, and potentially a second year. The whole study could last up to 138 weeks. This study is important to see if efgartigimod can be a safe and effective treatment option for young people with ITP.
एक नजर में
यह अध्ययन किस बारे में है?
This study is looking into a new medicine called efgartigimod for young people aged 12 to 17 who have a type of chronic Immune Thrombocytopenia (ITP). ITP is a condition where the body's immune system mistakenly attacks and destroys its own platelets, which are tiny blood cells that help stop bleeding. 'Chronic' means the condition has been present for a long time. The main goal of this particular study is to work out the most effective dose of efgartigimod, given as an intravenous (IV) drip, to help these young people.
Finding the right dose is really important because it ensures the medicine is both safe and works as well as it can. By focusing on young people, researchers hope to provide a new treatment option specifically tailored for this age group, who sometimes don't respond well to existing treatments or need other options. The study also aims to understand how efgartigimod works in the body and if it can help increase platelet numbers to a healthier level, reducing the risk of bleeding.
Ultimately, the findings from this study could lead to efgartigimod becoming a widely available and approved treatment for young people living with chronic ITP, potentially improving their quality of life and reducing the impact of the condition. It’s part of a larger effort to find better ways to manage ITP for everyone affected.
मुख्य निष्कर्ष
- This study is testing a new medicine, efgartigimod, for young people (12-17 years old) with long-term ITP.
- It aims to find the right dose for this age group to help increase platelet counts.
- Participants will first receive either the study medicine or a dummy treatment, then all will receive the study medicine.
- The study involves regular visits, IV treatments, blood tests, and could last over two years.
- This research hopes to provide a new treatment option for young people with ITP.
- You can withdraw from the study at any time if you decide it's not for you.
कौन पात्र हो सकता है?
This study is looking for young people aged between 12 and 17 years old who have been diagnosed with a type of ITP called 'primary ITP' for more than 12 months. Your doctor would have already tried to treat your ITP with at least one common treatment like steroids, IVIg, anti-D immunoglobulin, or other similar medicines, but these treatments haven't fully helped.
You should have shown some improvement to at least one of these past treatments (meaning your platelet count went up), but currently, your average platelet count needs to be quite low (less than 30 x10^9/L).
However, you can't join the study if your ITP is caused by another medical condition (this is called 'secondary ITP'), or if you have a different type of low platelet count not related to the immune system. You also wouldn't be able to take part if you have a history of serious or critical bleeding due to ITP, or if you have a family history of inherited low platelets.
क्या यह अध्ययन आपके लिए उपयुक्त हो सकता है?
यह देखने के लिए इन त्वरित प्रश्नों का उत्तर दें कि क्या आप पात्र हो सकते हैं। यह केवल एक मार्गदर्शिका है — अंतिम निर्णय शोध टीम द्वारा लिया जाता है।.
- क्या आपकी उम्र 12 से 17 वर्ष के बीच है?
- Have you been diagnosed with primary ITP for over 12 months?
- Have you tried at least one ITP treatment (like steroids or IVIg) before?
- Did your platelet count improve after one of those past treatments?
- Is your current average platelet count less than 30 x10^9/L (meaning quite low)?
- Do you NOT have ITP due to another medical condition or a family history of inherited low platelets?
भागीदारी में क्या शामिल है?
Taking part in this study involves several stages over a long period, potentially up to 138 weeks (about 2 years and 7 months). Initially, you'll be part of a 'double-blind' stage for up to 24 weeks. This means neither you, your family, nor your study doctors will know if you're receiving the study medicine (efgartigimod) or a dummy medicine (placebo) given through an IV drip. Everyone has a 2-in-3 chance of getting the active drug during this time.
After this, everyone who continues in the study will definitely receive efgartigimod through an IV drip during an 'open-label' period for at least one year. There's an option to continue for a second year if you and your doctor agree. Throughout the study, you'll have regular visits to the clinic for check-ups, blood tests (to measure your platelet count and overall health), and to receive your treatment. There will also be a follow-up period of about 8 weeks after you stop taking the study medicine to ensure everything is okay. Detailed information about the schedule of visits and tests will be provided by the study team.
संभावित जोखिम और लाभ
स्थान (26)
- Centre Hospitalier Universitaire de Bordeaux Groupe Hospitalier Pellegrin Hopital des Enfantsसत्यापित पोस्टकोडबोर्दो, फ्रांस· भर्ती
- Centre Hospitalier Universitaire de Grenoble - Hopital Couple - Enfantसत्यापित पोस्टकोडLa Tronche, France· भर्ती
- CHU de Nancy Hopitaux de Braboisसत्यापित पोस्टकोडVandœuvre-lès-Nancy, France· भर्ती
- Charite - Universitaetsmedizin Berlin - Campus Virchow-Klinikum (CVK)सत्यापित पोस्टकोडबर्लिन, जर्मनी· भर्ती
- Universitaetsklinikum Freiburg Kinder - Kinder- und Jugendklinikसत्यापित पोस्टकोडफ्राइबर्ग इम ब्रिसगाउ, जर्मनी· भर्ती
- Gaslini Children's Hospitalसत्यापित पोस्टकोडGenoa, Italy· भर्ती
- Fondazione IRCCS San Gerardo dei Tintoriसत्यापित पोस्टकोडMonza, Italy· भर्ती
- Bambino Gesu Children's Hospitalसत्यापित पोस्टकोडरोम, इटली· भर्ती
- A.O.U. Citta della Salute e della Scienza di Torino - Ospedale Infantile Regina Margheritaसत्यापित पोस्टकोडTorino, Italy· भर्ती
- Hokkaido University Hospitalसत्यापित पोस्टकोडSapporo, Japan· भर्ती
- Hyogo Prefectural Kobe Children's Hospitalसत्यापित पोस्टकोडKobe, Japan· भर्ती
- Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospitalसत्यापित पोस्टकोडOsaka, Japan· भर्ती
सामान्य प्रश्न
What is ITP?
ITP (Immune Thrombocytopenia) is a blood disorder where your body's immune system attacks and destroys its own platelets, which are essential for blood clotting. This can lead to bruising and bleeding.
What is efgartigimod?
Efgartigimod is an investigational medicine being tested to see if it can help increase platelet counts in people with chronic ITP. It's given as an IV (intravenous) drip.
'प्लेसबो' क्या है?
A placebo is a substance that looks exactly like the study medicine but doesn't contain any active drug. It helps researchers understand if the benefits observed are truly due to the new medicine.
मैं अध्ययन में कितने समय तक रहूँगा?
The study could last for up to 138 weeks, or about 2 and a half years, including different treatment periods and a follow-up stage.
क्या मैं अध्ययन में भाग लेना बंद कर सकता हूँ यदि मैं चाहूँ?
Yes, you can choose to leave the study at any time, for any reason, without it affecting your future medical care.
और अधिक जानने के लिए कैसे पता करें
Sabine Coppieters, MD
किसी अध्ययन में भाग लेने का निर्णय लेने से पहले हमेशा अपने जीपी या विशेषज्ञ से बात करें।.
भाग लेने में रुचि रखते हैं?
चर्चा
समुदाय चर्चा
हमारे फोरम द्वारा संचालित community.patient.info. कृपया सम्मानजनक रहें — यह चिकित्सा सलाह नहीं है।.